{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:41:02Z","timestamp":1791726062430,"version":"4.3.4"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejps.2024.106915","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T06:26:06Z","timestamp":1727331966000},"page":"106915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Evaluation and application of population pharmacokinetic models for optimising linezolid treatment in non-adherence multidrug-resistant tuberculosis patients"],"prefix":"10.1016","volume":"203","author":[{"given":"Rong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2024.106915_bib0001","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01381-21","article-title":"Linezolid population pharmacokinetics in south african adults with drug-resistant tuberculosis","volume":"65","author":"Abdelwahab","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2024.106915_bib0002","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper( )","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.ejps.2024.106915_bib0003","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis","volume":"15","author":"Agyeman","year":"2016","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"10.1016\/j.ejps.2024.106915_bib0004","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1128\/AAC.47.1.416-417.2003","article-title":"In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs","volume":"47","author":"Alcala","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2024.106915_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01174-20","article-title":"Population pharmacokinetics of linezolid in tuberculosis patients: dosing regimen simulation and target attainment analysis","volume":"64","author":"Alghamdi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2024.106915_bib0006","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/AAC.46.11.3484-3489.2002","article-title":"In vivo pharmacodynamics of a new oxazolidinone (linezolid)","volume":"46","author":"Andes","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2024.106915_bib0007","doi-asserted-by":"crossref","first-page":"e00004","DOI":"10.1002\/psp4.4","article-title":"Quantification of the forgiveness of drugs to imperfect adherence","volume":"4","author":"Assawasuwannakit","year":"2015","journal-title":"CPT. Pharmacometrics. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106915_bib0008","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40262-022-01125-2","article-title":"A review of population pharmacokinetic analyses of linezolid","volume":"61","author":"Bandin-Vilar","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106915_bib0009","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10928-011-9196-2","article-title":"A Bayesian approach for the estimation of patient compliance based on the last sampling information","volume":"38","author":"Barriere","year":"2011","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2024.106915_bib0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS. J."},{"key":"10.1016\/j.ejps.2024.106915_bib0011","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1128\/AAC.49.9.3676-3681.2005","article-title":"Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings","volume":"49","author":"Beringer","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2024.106915_bib0012","doi-asserted-by":"crossref","first-page":"e01741","DOI":"10.1128\/mBio.01741-15","article-title":"Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy","volume":"6","author":"Brown","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.ejps.2024.106915_bib0013","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijantimicag.2016.08.023","article-title":"Therapeutic drug management of linezolid: a missed opportunity for clinicians?","volume":"48","author":"Cattaneo","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejps.2024.106915_bib0014","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2024.106915_bib0015","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s10928-021-09777-6","article-title":"What should patients do if they miss a dose of medication? A theoretical approach","volume":"48","author":"Counterman","year":"2021","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2024.106915_bib0016","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/infdis\/jir662","article-title":"Drug forgiveness and interpatient pharmacokinetic variability in tuberculosis","volume":"204","author":"Dartois","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejps.2024.106915_bib0017","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1128\/AAC.49.6.2367-2371.2005","article-title":"Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses","volume":"49","author":"Dehghanyar","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2024.106915_bib0018","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00228-022-03340-z","article-title":"Applying pharmacokinetic\/pharmacodynamic measurements for linezolid in critically ill patients: optimizing efficacy and reducing resistance occurrence","volume":"78","author":"El-Gaml","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106915_bib0019","article-title":"Examining nonadherence in the treatment of tuberculosis: the patterns that lead to failure","author":"Fox","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106915_bib0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13318-019-00598-0","article-title":"How to handle delayed or missed doses: a population pharmacokinetic perspective","volume":"45","author":"Gu","year":"2020","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106915_bib0021","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.ijantimicag.2018.01.021","article-title":"Population pharmacokinetics\/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy","volume":"51","author":"Ide","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejps.2024.106915_bib0022","article-title":"Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis","author":"Imperial","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2024.106915_bib0023","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.qai.0000242449.67155.1a","article-title":"A once-daily lopinavir\/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen","volume":"43","author":"Johnson","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ejps.2024.106915_bib0024","first-page":"789","article-title":"A review of population pharmacokinetic analyses of linezolid","volume":"61","author":"Kawaguchi","year":"2022","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.ejps.2024.106915_bib0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/(SICI)1520-6017(200002)89:2<155::AID-JPS3>3.0.CO;2-2","article-title":"Inter-study variability in population pharmacokinetic meta-analysis: when and how to estimate it?","volume":"89","author":"Laporte-Simitsidis","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2024.106915_bib0026","first-page":"e921","article-title":"Handling delayed or missed dose of antiseizure medications: a model-informed individual remedial dosing","volume":"100","author":"Li","year":"2023","journal-title":"Neurology."},{"key":"10.1016\/j.ejps.2024.106915_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.967311","article-title":"Expert consensus statement on therapeutic drug monitoring and individualization of linezolid","volume":"10","author":"Lin","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.ejps.2024.106915_bib0028","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2006.04.017","article-title":"High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency","volume":"28","author":"Lin","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejps.2024.106915_bib0029","first-page":"187","article-title":"Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance","volume":"2","author":"Lipsitch","year":"1998","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.ejps.2024.106915_bib0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bcp.13431","article-title":"External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients","volume":"84","author":"Mao","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106915_bib0031","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/AAC.01411-05","article-title":"Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones","volume":"50","author":"McKee","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2024.106915_bib0032","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/AAC.47.2.548-553.2003","article-title":"Population pharmacokinetics of linezolid in patients treated in a compassionate-use program","volume":"47","author":"Meagher","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2024.106915_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14040753","article-title":"Model-informed precision dosing of linezolid in patients with drug-resistant tuberculosis","volume":"14","author":"Mockeliunas","year":"2022","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejps.2024.106915_bib0034","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/clpt.2010.171","article-title":"Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics","volume":"88","author":"Osterberg","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106915_bib0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jinf.2017.08.005","article-title":"Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the national clinical center for tuberculosis in China: a five-year review","volume":"75","author":"Pang","year":"2017","journal-title":"J. Infect."},{"key":"10.1016\/j.ejps.2024.106915_bib0036","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcpt.12797","article-title":"A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients?","volume":"121","author":"Pea","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejps.2024.106915_bib0037","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2024.106915_bib0038","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1124\/dmd.106.013755","article-title":"Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients","volume":"35","author":"Plock","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106915_bib0039","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.15368","article-title":"Parametric population pharmacokinetics of linezolid: a systematic review","author":"Qin","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106915_bib0040","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106915_bib0041","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jac\/dkh119","article-title":"Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis","volume":"53","author":"Rodriguez","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2024.106915_bib0042","doi-asserted-by":"crossref","first-page":"502","DOI":"10.5588\/ijtld.10.0238","article-title":"Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis","volume":"15","author":"Schon","year":"2011","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.ejps.2024.106915_bib0043","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some Suggestions for Measuring Predictive Performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejps.2024.106915_bib0044","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF01061728","article-title":"Estimation of population characteristics of pharmacokinetic parameters from routine clinical data","volume":"5","author":"Sheiner","year":"1977","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejps.2024.106915_bib0045","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/00912709922011962","article-title":"A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam","volume":"39","author":"Sisson","year":"1999","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106915_bib0046","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejps.2024.106915_bib0047","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1183\/09031936.00135014","article-title":"Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains","volume":"45","author":"Sotgiu","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejps.2024.106915_bib0048","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/infdis\/jir658","article-title":"Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability","volume":"204","author":"Srivastava","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejps.2024.106915_bib0049","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106915_bib0050","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/bcp.15102","article-title":"Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients","volume":"88","author":"Tietjen","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106915_bib0051","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/bcp.13262","article-title":"Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients","volume":"83","author":"Tsuji","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106915_bib0052","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/14787210.2016.1225498","article-title":"Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index","volume":"14","author":"Wasserman","year":"2016","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"key":"10.1016\/j.ejps.2024.106915_bib0053","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/bdd.255","article-title":"Linezolid absolute bioavailability and the effect of food on oral bioavailability","volume":"22","author":"Welshman","year":"2001","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2024.106915_bib0054","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12879-021-05870-w","article-title":"Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial","volume":"21","author":"Weng","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ejps.2024.106915_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105578","article-title":"Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: the example of tacrolimus","volume":"167","author":"Woillard","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejps.2024.106915_bib62","article-title":"WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment-Drug-Resistant Tuberculosis Treatment, 2022 update","year":"2022","journal-title":"Geneva"},{"key":"10.1016\/j.ejps.2024.106915_bib0056","first-page":"1014","article-title":"Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes","volume":"28","author":"Wynalda","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106915_bib0057","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/jac\/dky500","article-title":"Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia","volume":"74","author":"Xie","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2024.106915_bib0058","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijantimicag.2013.03.002","article-title":"In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates","volume":"42","author":"Yip","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejps.2024.106915_bib0059","article-title":"Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106915_bib0060","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bcp.12830","article-title":"External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients","volume":"81","author":"Zhao","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106915_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106589","article-title":"Linezolid pharmacokinetics\/pharmacodynamics-based optimal dosing for multidrug-resistant tuberculosis","author":"Zhou","year":"2022","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724002288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724002288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T09:26:12Z","timestamp":1730366772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724002288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":62,"alternative-id":["S0928098724002288"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106915","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation and application of population pharmacokinetic models for optimising linezolid treatment in non-adherence multidrug-resistant tuberculosis patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106915"}}